| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC1895 |
| Trial ID | NCT03528421 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | IM19 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Unknown |
| Title | Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients |
| Year | 2018 |
| Country | China |
| Company sponsor | Beijing Immunochina Medical Science & Technology Co., Ltd. |
| Other ID(s) | YMCART201705 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||||||||
|
|||||||||||||